[Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary].
Kiss LS, Szamosi T, Molnár T, Miheller P, Lakatos L, Vincze A, Palatka K, Bartha Z, Gasztonyi B, Salamon A, Horváth G, Tóth GT, Farkas K, Banai J, Tulassay Z, Nagy F, Szenes M, Veres G, Lovász BD, Végh Z, Golovics PA, Szathmári M, Papp M, Lakatos PL.
Kiss LS, et al. Among authors: lakatos l, lakatos pl.
Orv Hetil. 2011 Sep 4;152(36):1433-42. doi: 10.1556/OH.2011.29200.
Orv Hetil. 2011.
PMID: 21865144
Hungarian.